MX360640B - Diagnosis e imagenologia de cancer. - Google Patents

Diagnosis e imagenologia de cancer.

Info

Publication number
MX360640B
MX360640B MX2012010119A MX2012010119A MX360640B MX 360640 B MX360640 B MX 360640B MX 2012010119 A MX2012010119 A MX 2012010119A MX 2012010119 A MX2012010119 A MX 2012010119A MX 360640 B MX360640 B MX 360640B
Authority
MX
Mexico
Prior art keywords
imaging
mammal
cancer diagnosis
stop
cell cycle
Prior art date
Application number
MX2012010119A
Other languages
English (en)
Other versions
MX2012010119A (es
Inventor
S Gray Lloyd
Original Assignee
Tau Therapeutics Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics Llc Star filed Critical Tau Therapeutics Llc Star
Publication of MX2012010119A publication Critical patent/MX2012010119A/es
Publication of MX360640B publication Critical patent/MX360640B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para crear imagen de una enfermedad o condición en un mamífero, que incluye los pasos de: administrar una cantidad terapéuticamente efectiva de un inhibidor de ciclo celular para detener efectivamente la proliferación de células eucarióticas en un punto de control del ciclo celular entre las fases G1 y S, detener la administración del inhibidor de ciclo celular durante un periodo, administrar un marcador el mamífero y crear imagen del mamífero.
MX2012010119A 2010-03-01 2011-02-28 Diagnosis e imagenologia de cancer. MX360640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30903010P 2010-03-01 2010-03-01
PCT/US2011/026416 WO2011109262A2 (en) 2010-03-01 2011-02-28 Cancer diagnosis and imaging

Publications (2)

Publication Number Publication Date
MX2012010119A MX2012010119A (es) 2012-09-12
MX360640B true MX360640B (es) 2018-11-09

Family

ID=44542787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010119A MX360640B (es) 2010-03-01 2011-02-28 Diagnosis e imagenologia de cancer.

Country Status (13)

Country Link
US (1) US9427429B2 (es)
EP (1) EP2542155B1 (es)
JP (1) JP6017964B2 (es)
KR (1) KR101821343B1 (es)
CN (1) CN102781316B (es)
AU (1) AU2011223883B2 (es)
CA (1) CA2787673A1 (es)
ES (1) ES2557407T3 (es)
IL (1) IL221035A0 (es)
MX (1) MX360640B (es)
SG (2) SG183114A1 (es)
WO (1) WO2011109262A2 (es)
ZA (1) ZA201205377B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576191C (en) * 2004-08-20 2013-03-19 University Of Virginia Patent Foundation T type calcium channel inhibitors
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
EP3487516A1 (en) * 2016-07-19 2019-05-29 Bristol-Myers Squibb Company Radioligands for imaging the ido1 enzyme
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219609A (en) 1968-07-19 1971-01-20 Koninklijke Pharma Fab Nv Diphenylmethoxyethylamino derivatives
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US4091103A (en) 1976-06-23 1978-05-23 Ciba-Geigy Corporation Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives
JPS59161392A (ja) 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
US4906646A (en) 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
FR2601366B1 (fr) 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
DE68924456T2 (de) 1988-08-02 1996-05-30 Nissan Chemical Ind Ltd Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel.
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
FR2636946B1 (fr) 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0467435A3 (en) 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6413967B1 (en) 1995-03-30 2002-07-02 The University Of Virginia Patents Foundation Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy
CA2228604A1 (en) 1995-09-08 1997-03-13 Jan E. Schnitzer Isolation of microdomains of caveolae and gpi-anchored proteins
US5981539A (en) 1995-09-15 1999-11-09 Neurosearch A/S Piperidine compounds as calcium channel blockers
DK0882061T3 (da) 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6191156B1 (en) 1997-04-11 2001-02-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating bladder dysfunction
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
EP1042468B1 (en) 1997-12-03 2006-10-18 Merck & Co., Inc. Low-voltage activated calcium channel compositions and methods
EP1036170A1 (en) 1997-12-05 2000-09-20 Loyola University Of Chicago T-type voltage-gated calcium channels and method of using same
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
JPH11246417A (ja) 1998-03-04 1999-09-14 Nissan Chem Ind Ltd 糖尿病性腎症治療用医薬組成物
JP2002525077A (ja) 1998-08-26 2002-08-13 サウス、アラバマ、メディカル、サイエンス、ファウンデーション Ｔ型カルシウムチャンネル
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6946475B1 (en) 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
ATE269848T1 (de) 1999-04-07 2004-07-15 Univ Virginia Calciumkanalblocker als antikrebsmittel
US7195783B2 (en) 1999-07-09 2007-03-27 Fx Life Sciences International Gmbh Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE357257T1 (de) 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
JP2005501840A (ja) 2001-07-23 2005-01-20 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト 癌の改良された治療のための手段および方法
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10227511A1 (de) 2002-06-19 2004-01-08 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040127471A1 (en) 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
RU2326886C2 (ru) 2003-03-28 2008-06-20 Ниссан Кемикал Индастриз, Лтд. Блокатор кальциевых каналов т-типа
TW200528107A (en) 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
AU2011203315B8 (en) 2004-02-11 2012-02-16 University Of Virginia Patent Foundation Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
US20080160009A1 (en) 2004-02-11 2008-07-03 Gray Lloyd S Inhibiting Cav3 Isoforms and the 25B Splice Varients for the Diagnosis and Treatment of Cancer
EP1730173A4 (en) 2004-02-18 2008-10-08 Merck & Co Inc NUCLEIC ACID MOLECULES COORDINATING TO NEW MACHINE CALCIUM CHANNEL PROPERTIES ACTIVATED BY LOW VOLTAGES, DESCRIBED AS ALPHA 1H, PROCEDED PROTEINS, AND METHOD OF USE THEREOF
US20060003020A1 (en) 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2006003020A1 (en) 2004-07-02 2006-01-12 L'oreal Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof
US20100222406A1 (en) 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
CA2576186A1 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CA2576191C (en) 2004-08-20 2013-03-19 University Of Virginia Patent Foundation T type calcium channel inhibitors
US20120264804A1 (en) 2004-08-20 2012-10-18 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US7851431B2 (en) 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
CN101528768A (zh) * 2006-08-10 2009-09-09 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
JP5339291B2 (ja) * 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
US20080248033A1 (en) 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20100087398A1 (en) 2007-05-02 2010-04-08 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
JP5029328B2 (ja) 2007-12-05 2012-09-19 マツダ株式会社 自動車の前部車体構造
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
KR20120030112A (ko) 2009-06-05 2012-03-27 타우 쎄라퓨틱스 엘엘씨 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
EP2755674A4 (en) 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS

Also Published As

Publication number Publication date
AU2011223883A1 (en) 2012-09-13
HK1179143A1 (zh) 2013-09-27
KR20130014506A (ko) 2013-02-07
SG183114A1 (en) 2012-09-27
IL221035A0 (en) 2012-09-24
JP2013521287A (ja) 2013-06-10
EP2542155B1 (en) 2015-11-04
MX2012010119A (es) 2012-09-12
US20120321561A1 (en) 2012-12-20
AU2011223883B2 (en) 2015-10-08
KR101821343B1 (ko) 2018-01-23
WO2011109262A2 (en) 2011-09-09
ES2557407T3 (es) 2016-01-25
WO2011109262A3 (en) 2011-11-17
CN102781316A (zh) 2012-11-14
EP2542155A2 (en) 2013-01-09
US9427429B2 (en) 2016-08-30
CA2787673A1 (en) 2011-09-09
ZA201205377B (en) 2013-09-25
JP6017964B2 (ja) 2016-11-02
EP2542155A4 (en) 2013-07-17
SG10201501496TA (en) 2015-04-29
CN102781316B (zh) 2016-07-06

Similar Documents

Publication Publication Date Title
ES2557407T3 (es) Procedimiento de imaginología de una enfermedad
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MX2021009625A (es) Métodos para incrementar el crecimiento en sujetos pediátricos que tienen enfermedad de hígado colestásico.
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX363000B (es) Composiciones y usos de las mismas para tratar la inflamación.
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
MX2013002372A (es) Metodos para recelularizar un tejido o un organo para una transplantabilidad mejorada.
PH12016500024A1 (en) Bromodomain inhibitor
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
CL2015002210A1 (es) Conjugados de ciclosporina a y esteroide
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
CY1123614T1 (el) Μεθοδος θεραπειας δυσκινησιας
MX2015014344A (es) Terapia contra el cancer.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
AR111236A1 (es) Uso intradialítico de tiosulfato de sodio
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer

Legal Events

Date Code Title Description
FG Grant or registration